chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Non itching rash on chest and upper abdomen; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration in the left arm on 21Apr2021 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. The patients' medical history included migraines. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included erenumab (AIMOVIG MONTHLY INJECTION), topiramate (TROKENDI XR 50MG) and "vitam"; all taken for unknown indications from unspecified dates and unknown if ongoing. The patient previously received nortriptyline (MANUFACTURER UNKNOWN) and experienced a drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration in the left arm on 31Mar2021 at 15:45 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 23Apr2021 at 06:00, 2 days after the second dose, the patient experienced a non-itching rash on chest and upper abdomen. She noticed it first thing in the morning. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event non-itching rash on chest and upper abdomen was not resolved at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Hypoaesthesia, Nausea, Neck pain, Pain
Clinical narrative: Chills; Body ache; Nausea; Numbness in left side of face started about 5.5 hours after the shot in left arm.; Also had neck pain with it.; This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0169) via an unspecified route of administration in the left arm on 21Apr2021 at 10:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. The patient had unspecified medical history. The patient had no allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included metformin hydrochloride; sitagliptin phosphate monohydrate (JANUMET), pantoprazole (MANUFACTURER UNKNOWN), dapagliflozin propanediol monohydrate (FARXIGA) and lisinopril (MANUFACTURER UNKNOWN), all used for an unknown indication, from an unknown date and unknown if ongoing.  The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 30Mar2021 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 14:45, the patient experienced numbness in left side of face starting about 5.5 hours after the shot in left arm; she also had neck pain with vaccine, chills, body ache and nausea. The adverse event did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the reported events. The clinical outcome of the events numbness in face cleared within 24 hours followed by chills, body ache, nausea and neck pain was resolved on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dyspepsia, Headache, Pain, Pyrexia
Clinical narrative: Fever; Chills; Body aches; Headaches; Heartburn; This is a spontaneous report from a contactable healthcare professional. A 31-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the left arm on 22Apr2021 (at the age of 31-year-old) as a single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously took amoxicillin (MANUFACTURER UNKNOWN) for unknown indication on unknown date and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the left arm on 01Apr2021 (at the age of 31-year-old) as a single dose for COVID-19 immunization. On 22Apr2021, the patient experienced fever, chills, body aches, headaches and heartburn. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, body aches, headaches and heartburn was unknown at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Pain, Pyrexia
Clinical narrative: Fever; Headache; pain at injection site; Exhaustion; chills; aches; This is a spontaneous report from a non-contactable consumer, the patient. A 23-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 20Apr2021 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. The patient had no known allergies to medication, food or any other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included birth control pills (MANUFACTURER UNKNOWN) from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 01Apr2021 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. On 20Apr2021, the patient experienced fever, headache, pain at injection site, exhaustion, chills and aches. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of reported events. The clinical outcome of the events fever, headache, pain at injection site, exhaustion, chills and aches were recovered on an unknown date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Fever; Headache; pain at injection site; Exhaustion; chills; aches; This is a spontaneous report from a non-contactable consumer, the patient. A 23-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 20Apr2021 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. The patient had no known allergies to medication, food or any other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included birth control pills (MANUFACTURER UNKNOWN) from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 01Apr2021 (at the age of 23-years-old) as a single dose for COVID-19 immunisation. On 20Apr2021, the patient experienced fever, headache, pain at injection site, exhaustion, chills and aches. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of reported events. The clinical outcome of the events fever, headache, pain at injection site, exhaustion, chills and aches were recovered on an unknown date in Apr2021.  No follow-up attempts are possible. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Rash on neck; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 20Apr2021 at 16:30 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included rash (Also usually get the same type of rash when she has a common cold). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any medications within two weeks of the COVID-19 vaccine. The patient previously took first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 30Mar2021 at 16:15 as a single dose for COVID-19 immunisation. On 22Apr2021, the patient experienced rash on neck. Patient also stated that she also usually gets the same type of rash when she has a common cold. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event rash on neck was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling
Clinical narrative: Swelling in arm; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Apr2021 at 13:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history included autoimmune disease. The patient had no known allergies to food, medications or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 01Apr2021 at 13:00 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. On 23Apr2021 at 09:00, the patient experienced swelling in her arm. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. Therapeutic measures were taken as a result of swelling in arm and included treatment with unspecified allergic medication. The clinical outcome of the event swelling in arm was unknown at the time of this report.   No follow-up attempts are required; information about lot number cannot be obtained; No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Migraine, Pain, Pyrexia
Clinical narrative: Fever; Chills; Bad migraine; Body aches; This is a spontaneous report from a non-contactable consumer, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 14Apr2021 at 14:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included overweight. The patient was not allergic to medications, food, or other products. The patient did not receive any medications within two weeks of vaccination.  The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 24Mar2021 at 14:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Apr2021 at 12:00, day after the vaccination, the patient experienced, fever, chills, bad migraine and body aches. Only lasted on 16Apr2021, that next day, and was fine thereafter. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fever, chills, bad migraine and body aches was resolved on 16Apr2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 16.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Nausea
Clinical narrative: Dizziness; Nausea; This is a spontaneous report from a contactable pharmacist. A 16-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via intramuscular route of administration in the left arm on 14Apr2021 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not have allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not take any concomitant medications. On 14Apr2021 the patient experienced nausea and dizziness following the 15 minutes observation period and was advised to sit. The patient denied any shortness of breath and did not eat anything that morning. The vital signs were all within normal limits. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the events and included juice and crackers. The patient reported improvement after hydration and snacks.  The clinical outcome of the event nausea and dizziness were resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea, SARS-CoV-2 test, Vaginal haemorrhage
Clinical narrative: I had vaginal bleeding/spotting; slight cramping two weeks after my menstrual period; This is a spontaneous report from a contactable other hcp (patient). A 25-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection), via an unspecified route of administration, administered in Arm Left on 23Mar2021 08:30 (at the age of 25-year-old) as dose number unknown, single for covid-19 immunization. Medical history included asthma from an unknown date. Prior to vaccination, was the patient diagnosed with COVID-19 as reported as no. Concomitant medications included montelukast taken for an unspecified indication. The patient had vaginal bleeding/spotting and slight cramping two weeks after my menstrual period on 28Mar2021 at 07:00. This was not normal for me as patient always have her periods at the same time each month since patient was on birth control. Event resulted in doctor or other healthcare professional office/clinic visit. No treatment was received. The patient underwent lab tests and procedures which included sars-cov-2 test was negative (nasal swab) on 21Jan2021. The clinical outcome of events was recovered in Apr2021.  This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information is expected.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Sore arm approximately 24 hours in duration; This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration in the right arm on 19Mar2021 at 16:00 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Mar2021 at 16:00, the patient experienced sore arm approximately 24 hours in duration. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of sore arm. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event sore arm approximately 24 hours in duration was recovered on 20Mar2021. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on an unknown date in 2021, as a single dose for COVID-19 immunisation.  No follow-up attempts are possible. No further information is expected.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Pruritus
Clinical narrative: Red dots all over body; itchy lightly; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Apr2021 at 17:00 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. The patient did not have any medical history. The patient did not have allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not receive any medication within two weeks of vaccination. On 21Apr2021 at 16:00, the patient had red dots all over the body which was started to appear on the 3rd day. It was the 5th day and the patient still had them. They itched lightly. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of adverse events. The clinical outcome of the event red dots and itchy was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Nightmare, Sleep disorder, Somnolence
Clinical narrative: Nightmares; Fatigue; Groggy feeling; Nightmares have continued nightly and wake me up; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 21Apr2021 at 17:30 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included norethisterone acetate, ethinylestradiol, ferrous fumarate (LOESTRIN 24 FE) taken for an unspecified indication from an unknown date. The patient previously took cephalosporin (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient previously received the first dose BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the left arm on 31Mar2021 at 16:15 (at the age of 30-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 at 06:30, the patient experienced nightmares, fatigue and groggy feeling. Nightmares had continued nightly and woken the patient, she never remembered the dreams or woke up from them, ever. The only thing in her life that had changed is that she had received the second dose. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events nightmares, fatigue and groggy feeling were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pain, Paraesthesia, Pyrexia
Clinical narrative: Fever; Chills; Fatigue; Body aches; Tingling in face and arms; This is a spontaneous report from a contactable other healthcare professional, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Jan2021 at 16:30 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. Medical history included psoriatic arthritis. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included leflunomide (MANUFACTURER UNKNOWN) from an unknown date for an unknown indication and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date, as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Jan2021 at 07:00, the patient experienced fever, chills, fatigue, body aches and tingling in face and arms. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills, fatigue, body aches and tingling in face and arms was resolved on an unknown date in 2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Tinnitus
Clinical narrative: Continuous tinnitus in both ears; This is a spontaneous report from a non-contactable consumer, the patient. A 47-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: ER8733) via an unspecified route of administration on 05Apr2021 (at the age of 47-year-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. On 08Apr2021, the patient experienced continuous tinnitus in both ears. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event continuous tinnitus in both ears was not recovered at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Pruritus, SARS-CoV-2 test, Skin warm, Urticaria
Clinical narrative: Very hot; skin is burning and it is all over; itchiness all over body; Hives all over body; This is a spontaneous report from a contactable consumer, the patient. A 27-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 11Apr2021 (at the age of 27-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included losartan (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN) and ibuprofen (MANUFACTURER UNKNOWN), ethinylestradiol, norgestimate (TRI-SPRINTEC): all for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 21Mar2021 at 15:30 (at the age of 27-year-old) as a single dose for COVID-19 immunisation. On 12Apr2021 at 23:00 the patient experienced hives and itchiness all over body, very hot like skin was burning and it was all over. On an unknown date, the patient underwent nasal swab, SARS CoV-2 test and the result was unknown. Since the vaccination, the patient had been tested for COVID-19. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events hives and itchiness all over body, very hot like her skin was burning and it was all over were not resolved at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Back pain, Headache, Pain, Pain in extremity
Clinical narrative: Headache; sore back; sore legs; joint pain in lower body; some arm; soreness; This is a spontaneous report from a non-contactable consumer, the patient. A 29-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: er8731) via an unspecified route of administration in the right arm on 19Apr2021 at 14:45 (at the age of 29-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. Concomitant medications were included as hormonal IUD (MANUFACTURER UNKNOWN) and ascorbic acid; cyanocobalamin; ergocalciferol; nicotinamide; pyridoxine hydrochloride; retinol; riboflavin; thiamine mononitrate (ONE-A-DAY WOMEN'S VITAMINS) started on an unknown date for unknown indications. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination.  The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: er8732) via an unspecified route of administration in the right arm on 29Mar2021 at 14:30 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. On 20Apr2021, the patient experienced headache, sore back, sore legs, joint pain in lower body, some arm and soreness. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events headache, sore back, sore legs, joint pain in lower body, some arm and soreness were recovered at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Vaccination site pain
Clinical narrative: Fever; Site injection pain; This is a spontaneous report from a non-contactable consumer. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration on 21Apr2021 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19.It was unknown whether the patient received any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On 21Apr2021, the patient developed fever and site injection pain. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fever and site injection pain were recovering at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dizziness, Fatigue, Nausea, Oropharyngeal pain
Clinical narrative: Sore throat; Fatigue; Weakness; Nausea; Dizziness; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 03Apr2021 at 10:30 (at the age of 45-year-old) as a single dose for COVID-19 immunisation. Medical history included allergy to tree nuts. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication taken within two weeks of vaccination was not reported. On 08Apr2021 at 16:00, the patient experienced sore throat, fatigue, weakness, nausea and dizziness. Since the vaccination, the patient had not been tested for COVID-19.  The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events sore throat, fatigue, weakness, nausea and dizziness was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Chapped lips, Palpitations, Urticaria
Clinical narrative: Hives in mouth, throat and on lips; Lips chapping; Mild heart palpitation; This is a spontaneous report from a non-contactable consumer, the patient. A 57-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO161) via an unspecified route of administration in the left arm on 16Apr2021 at 18:30 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to mangoes and cashews. The patient did not receive any other medications within 2 weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 16Apr2021 at 20:30, the patient experienced hives in mouth, throat and on lips, lips chapping and mild heart palpitation. The patient had lips chapping for 2 days and mild heart palpitations was there over 2 days. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events hives and palpitation were resolved on an unknown date in Apr2021, whereas the event chapped lips was resolved on 18Apr2021.   No follow-up attempts are possible. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Paraesthesia
Clinical narrative: Got a super strong tingle in lip area both lips and above and below; Got a burning sensation that was intense (almost like the feeling get if hands are super cold from snow and as they warm it burns) that lasted about 5 minutes.; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 24Apr2021 at 09:45 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure (BP), obesity and depression. The patient had known allergies to bee stings, lisinopril dihydrate (LISINOPRIL) and pethidine hydrochloride (DEMEROL). Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included levothyroxine (MANUFACTURER UNKNOWN), hydrochlorothiazide (MANUFACTURER UNKNOWN) and bupropion hydrochloride (WELLBUTRIN); all from unknown dates for unknown indications and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 31Mar2021 at 09:45 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021 at 10:00, about 7 minutes after the shot, the patient got a super strong tingle in lip area, both her lips and above and below. It lasted approximately an hour and when it started to go away, the patient got a burning sensation that was intense (almost like the feeling you get if your hands are super cold from snow and as they warm it burns) that lasted about 5 minutes and 4 hours later when she touched her lips, they were odd. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events super strong tingle in lip area, both her lips and above and below, burning sensation that was intense (almost like the feeling you get your hands are super cold from snow and as they warm it burns) was unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Balance disorder, Dizziness
Clinical narrative: Dizzy; lost balance on day 2 of dose1; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 22Apr2021 at 15:30 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included high cholesterol. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient received unspecified medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously took sulfamethoxazole; trimethoprim (BACTRIN) for unspecified indication from unknown date and experienced drug allergy. On 24Apr2021 at 17:00, the patient experienced dizzy and almost lost balance on day 2 of dose 1. Since the vaccination, the patient had not been tested for COVID-19. The events did not result in any of these doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event dizzy and lost balance on day 2 of dose1 was unknown at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Metallic taste; This is a spontaneous report from a non-contactable consumer, the patient. A 41-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 22Apr2021 at 15:00 (at the age of 41-year-old) as a single dose for COVID-19 immunisation. The patient had no relevant  medical history. The patient had no allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications within two weeks of the vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 the patient experienced metallic taste. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the event metallic taste was not resolved at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Breast pain, Eyelids pruritus, Oropharyngeal pain, Pruritus, Pyrexia
Clinical narrative: Scabby, itchy eyelid, swelling; Scabby, itchy eyelid, swelling; Scabbing, itchiness, pain, left breast; Scabby, itchy eyelid, swelling; Scabbing, itchiness, pain, left breast; Scabbing, itchiness, pain, left breast; Sore throat; Swollen tonsils; Mild fever; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an unspecified route on 13Apr2021 in the left arm (at an age of 29-years-old), as single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included cetirizine hydrochloride (ZYRTEC) 10mg for unspecified indication from unknown date and unknown if ongoing. The patient did not receive any other vaccination within 4 weeks of COVID vaccine. On 19Apr2021, approx. 6 days after shot, the patient experienced sore throat, swollen tonsils, mild fever. On 20Apr2021, approx. 7 days after shot, the patient experienced scabbing, itchiness, pain, left breast. On 22Apr2021, approx. 9 days after shot, the patient experienced scabby, itchy eyelid and swelling. Since the vaccination, the patient had not been tested for COVID-19. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events of sore throat, swollen tonsils, mild fever, scabbing, itchiness, pain, left breast, scabby, itchy eyelid and swelling were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Scab, Swelling of eyelid, Tonsillar hypertrophy
Clinical narrative: Scabby, itchy eyelid, swelling; Scabby, itchy eyelid, swelling; Scabbing, itchiness, pain, left breast; Scabby, itchy eyelid, swelling; Scabbing, itchiness, pain, left breast; Scabbing, itchiness, pain, left breast; Sore throat; Swollen tonsils; Mild fever; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via an unspecified route on 13Apr2021 in the left arm (at an age of 29-years-old), as single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included cetirizine hydrochloride (ZYRTEC) 10mg for unspecified indication from unknown date and unknown if ongoing. The patient did not receive any other vaccination within 4 weeks of COVID vaccine. On 19Apr2021, approx. 6 days after shot, the patient experienced sore throat, swollen tonsils, mild fever. On 20Apr2021, approx. 7 days after shot, the patient experienced scabbing, itchiness, pain, left breast. On 22Apr2021, approx. 9 days after shot, the patient experienced scabby, itchy eyelid and swelling. Since the vaccination, the patient had not been tested for COVID-19. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events of sore throat, swollen tonsils, mild fever, scabbing, itchiness, pain, left breast, scabby, itchy eyelid and swelling were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain
Clinical narrative: Left arm pit pain; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 16Apr2021 at 07:30 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Other medical history was reported as none. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 at 20:00, the patient experienced left arm pit pain. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as result of the event which included treatment with ibuprofen. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event left arm pit pain was recovering at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Illness, Inappropriate schedule of product administration, Pyrexia, Rash pruritic, SARS-CoV-2 test
Clinical narrative: Very sick; rash formed that itched; Fever; Dose 1: 05Apr2021 and Dose 2: 19Apr2021; This is a spontaneous report from a non-contactable consumer, the patient. A 36-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 19Apr2021 at 12:00 (at the age of 36-years-old), as a single dose for COVID-19 immunisation. Medical history included irritable bowel syndrome (IBS) and allergy to some tree nuts. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other medications within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 05Apr2021 at 12:00 (at the age of 36-years-old), as a single dose for COVID-19 immunisation. On 20Apr2021, the patient felt very sick after vaccination, then a rash formed that itched after the fever broke. Rash had persisted for several days. The patient underwent lab tests and procedures which included COVID-19 virus test (nasal swab) on an unknown date in Apr2021 and the result was unknown. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events sickness, rash, itchy and fever was recovered with lasting effects on an unknown date of Apr2021.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Hypoaesthesia, Paraesthesia
Clinical narrative: Numbness/tingling in left pink and ring finger within 5 minutes after injection; Numbness/tingling in left pink and ring finger within 5 minutes after injection; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Apr2021 at 10:00 (at the age of 25-year-old) as a single dose for COVID-19 immunisation. Medical history was reported as not applicable. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no known allergies to medications, food or other products. The patient did not take any other concomitant medications and did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 23Apr2021 at 10:00, within 5 minutes after injection, the patient experienced numbness/ tingling in the left pink and ring finger. The events did not result in doctors or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of numbness/ tingling in the left pink and ring finger. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events numbness/ tingling in the left pink and ring finger was not recovered at the time of this report.  No follow-up attempts are required. Information about lot number cannot be obtained. No further information is expected.